Journal: PLoS ONE

Article Title: Adjuvant Effect of Killed Propionibacterium acnes on Mouse Peritoneal B-1 Lymphocytes and Their Early Phagocyte Differentiation

doi: 10.1371/journal.pone.0033955

Figure Lengend Snippet: Peritoneal cells from P. acnes -, PS- or saline-treated mice were analyzed 24 h after treatment ( in vivo ). The non-adherent population of 5-day-old B-1b enriched cultures was also analyzed ( in vitro ). The cells were stained with mAbs to identify the B-1 cell subsets. (A to C) The small (R1) and large granular (R2) cells from the SSC-H×FSC-H dot plots are shown, followed by the CD23×CD19 analysis from R1 and R2 and the CD5×CD11b analysis from R3 and R4. (D and E) The absolute numbers of B-1b, B-1a and B-1c lymphocytes from mice treated with saline (control group), P. acnes and PS. The absolute numbers of the B-1a and B-1b lymphocytes are the sum of R1 and R2, and the B-1c values are derived from R1. The absolute cell number is the mean of two independent experiments with similar results. * p <0.05 compared to the control group. # p <0.05 between the P. acnes and PS treated groups.

Article Snippet: The stained cells were evaluated using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA), and the B-1a, B-1b and B-1c populations were analyzed by CellQuest Pro software (Becton Dickinson, San Jose, CA, USA).

Techniques: In Vivo, In Vitro, Staining, Derivative Assay

Journal: PLoS ONE

Article Title: Differential Regulation of Hepatic Transcription Factors in the Wistar Rat Offspring Born to Dams Fed Folic Acid, Vitamin B 12 Deficient Diets and Supplemented with Omega-3 Fatty Acids

doi: 10.1371/journal.pone.0090209

Figure Lengend Snippet: - Pup liver PPARα expression in different groups. - Pup liver PPARγ expression in different groups. - Pup liver SREBP-1c expression in different groups. - Pup liver LXRα expression in different groups. - Pup liver RXRα expression in different groups. Gene expression was carried out in pup liver using real time PCR. Data in each group is on 4 males and 4 females. The treatment groups were compared with the control group by ANOVA and the post-hoc least significant difference test. Data is presented as the mean ± SD of 2 ΔCT where ΔCT is CT (GAPDH) – CT (target gene). *p<0.05 as compared to control; **p<0.01 as compared to control; $p<0.05 as compared to FD group; $$p<0.01 as compared to FD group; @ p<0.05 as compared to BD group; @@ p<0.01 as compared to BD group. Control – Normal folic acid, normal vitamin B 12 ; FD– folic acid deficient; BD – vitamin B 12 deficient; FDO– folic acid deficient and omega-3 fatty acid supplementation; BDO– vitamin B 12 deficient and omega-3 fatty acid supplementation.

Article Snippet: There was no difference observed in the pup liver SREBP-1c expression between the micronutrient deficiency groups (FD and BD) and the control group.

Techniques: Expressing, Real-time Polymerase Chain Reaction

Journal: Diabetes Care

Article Title: Universal Subsidized Continuous Glucose Monitoring Funding for Young People With Type 1 Diabetes: Uptake and Outcomes Over 2 Years, a Population-Based Study

doi: 10.2337/dc21-1666

Figure Lengend Snippet: Demographic and clinical characteristics of the CGM and non-CGM cohorts

Article Snippet: Those choosing not to use CGM were older, had longer duration of diabetes, were more likely to be managed with a multiple daily insulin (MDI) regimen, and had higher baseline HbA 1c compared with those who elected to commence CGM use. table ft1 table-wrap mode="anchored" t5 caption a7 Variable CGM Non-CGM * All P value ‡ Test n = 2,625 n = 435 N = 3,060 Sex 0.067 Pearson χ 2 Female 1,283 (48.9) 192 (44.1) 1,475 (48.2) Male 1,342 (51.1) 243 (55.9) 1,585 (51.8) Age at baseline, † mean (SD), years 11.5 (4.1) 13.9 (3.8) 11.8 (4.1) <0.001 Two-sample t test Age at diagnosis, mean (SD), years 7.7 (3.9) 8.5 (4.3) 7.9 (4.0) <0.001 Two-sample t test Diabetes duration at baseline, † years 2.6 (0.3, 6.1) 4.5 (1.9, 8.1) 2.9 (0.3, 6.4) <0.001 Wilcoxon rank sum Insulin regimen <0.001 Pearson χ 2 MDI 1,113 (49.4) 242 (61.6) 1,355 (51.2) CSII 933 (41.4) 116 (29.5) 1,049 (39.6) BD 201 (8.9) 35 (8.9) 236 (8.9) HbA 1c at baseline, † mean (SD), % 8.3 (1.5) 8.6 (1.9) 8.4 (1.6) <0.001 Two-sample t test Open in a separate window Data are presented as n (%), median (interquartile range), or as indicated.

Techniques:

Journal: Diabetes Care

Article Title: Universal Subsidized Continuous Glucose Monitoring Funding for Young People With Type 1 Diabetes: Uptake and Outcomes Over 2 Years, a Population-Based Study

doi: 10.2337/dc21-1666

Figure Lengend Snippet: OR of HbA 1c <7% and HbA 1c ≥9% from 6 months before CGM start to 24 months after CGM start

Article Snippet: Those choosing not to use CGM were older, had longer duration of diabetes, were more likely to be managed with a multiple daily insulin (MDI) regimen, and had higher baseline HbA 1c compared with those who elected to commence CGM use. table ft1 table-wrap mode="anchored" t5 caption a7 Variable CGM Non-CGM * All P value ‡ Test n = 2,625 n = 435 N = 3,060 Sex 0.067 Pearson χ 2 Female 1,283 (48.9) 192 (44.1) 1,475 (48.2) Male 1,342 (51.1) 243 (55.9) 1,585 (51.8) Age at baseline, † mean (SD), years 11.5 (4.1) 13.9 (3.8) 11.8 (4.1) <0.001 Two-sample t test Age at diagnosis, mean (SD), years 7.7 (3.9) 8.5 (4.3) 7.9 (4.0) <0.001 Two-sample t test Diabetes duration at baseline, † years 2.6 (0.3, 6.1) 4.5 (1.9, 8.1) 2.9 (0.3, 6.4) <0.001 Wilcoxon rank sum Insulin regimen <0.001 Pearson χ 2 MDI 1,113 (49.4) 242 (61.6) 1,355 (51.2) CSII 933 (41.4) 116 (29.5) 1,049 (39.6) BD 201 (8.9) 35 (8.9) 236 (8.9) HbA 1c at baseline, † mean (SD), % 8.3 (1.5) 8.6 (1.9) 8.4 (1.6) <0.001 Two-sample t test Open in a separate window Data are presented as n (%), median (interquartile range), or as indicated.

Techniques:

Journal: Diabetes Care

Article Title: Universal Subsidized Continuous Glucose Monitoring Funding for Young People With Type 1 Diabetes: Uptake and Outcomes Over 2 Years, a Population-Based Study

doi: 10.2337/dc21-1666

Figure Lengend Snippet: Mean HbA 1c by age-group and CGM usage at baseline and 12 and 24 months after CGM start

Article Snippet: Those choosing not to use CGM were older, had longer duration of diabetes, were more likely to be managed with a multiple daily insulin (MDI) regimen, and had higher baseline HbA 1c compared with those who elected to commence CGM use. table ft1 table-wrap mode="anchored" t5 caption a7 Variable CGM Non-CGM * All P value ‡ Test n = 2,625 n = 435 N = 3,060 Sex 0.067 Pearson χ 2 Female 1,283 (48.9) 192 (44.1) 1,475 (48.2) Male 1,342 (51.1) 243 (55.9) 1,585 (51.8) Age at baseline, † mean (SD), years 11.5 (4.1) 13.9 (3.8) 11.8 (4.1) <0.001 Two-sample t test Age at diagnosis, mean (SD), years 7.7 (3.9) 8.5 (4.3) 7.9 (4.0) <0.001 Two-sample t test Diabetes duration at baseline, † years 2.6 (0.3, 6.1) 4.5 (1.9, 8.1) 2.9 (0.3, 6.4) <0.001 Wilcoxon rank sum Insulin regimen <0.001 Pearson χ 2 MDI 1,113 (49.4) 242 (61.6) 1,355 (51.2) CSII 933 (41.4) 116 (29.5) 1,049 (39.6) BD 201 (8.9) 35 (8.9) 236 (8.9) HbA 1c at baseline, † mean (SD), % 8.3 (1.5) 8.6 (1.9) 8.4 (1.6) <0.001 Two-sample t test Open in a separate window Data are presented as n (%), median (interquartile range), or as indicated.

Techniques: